Compare Amylx Pharmaceuticals Inc (AMLX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Under Armour Inc Class A trades at $6.72 (market cap $2.86B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| AMLX | UAA | |
|---|---|---|
Market Cap | $1.98B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $8.14 |
52-Week Low | $7.64 | $4.17 |
Enterprise Value | $1.70B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Under Armour (UAA) trades at $6.79, up 3.03% today, showing technical bullish momentum with moving averages supporting upward movement. However, the company faces fundamental challenges with negative net income margins (-9.98%) and declining revenue from $5.7B in 2024 to $5.2B in 2025. Recent earnings showed mixed results with a Q1 2026 miss, while cash flow remains negative at -$362M for 2025. The Dodge collaboration and Persona AI partnership represent strategic initiatives amid ongoing North American market weakness.
The outlook remains cautious with analyst consensus price target at $5.96 below current levels, reflecting concerns about profitability and revenue trends. Investment opportunity exists if international growth and cost management improve margins, but risks include persistent North American weakness, margin pressure, and negative cash flow generation. Wall Street sentiment leans neutral with 58% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
